- Home
- Our Services
- Model Informed Drug Development (MIDD)
- Population Pharmacokinetics
- Pharmacokinetics NCA
- Physiologically based Pharmacokinetic modeling
- Drug-Drug Interactions (DDI) analysis
- CDISC compliance of PK Data
- Modeling & Simulation
- Guiding dose selection
- Filing for health agencies
- Target-Mediated Drug Disposition
- QT / QTc Analysis (TQT) for cardiac safety
- Integrated Phase 1 Solutions
- Resources
- About us
- News
- Experts opinion: An update on tomorrow's solutions.
- New article: Unlocking the power of PBPK prediction
- 10 good reasons to choose modeling and simulation
- PhinC celebrates its 15th anniversary!
- PhinC launches SiMmAbs project
- Modeling & Simulation Strategies Must Be Integrated into Clinical Development
- PhinC joins French Tech
- Fexinidazole awarded a spot in 2020 medicines list
- CDISC standards by Michaël Boily
- Read our new article about PopPK
- Champions de la Croissance 2020
- PhinC participated at FDA event: PBPK best practices
- Development of a new intra-articular module
- The success of our PBPK symposium 2019
- PhInc. Modeling is launched
- EMA gave a positive opinion about Fexinidazole
- PhinC renews sponsorship to GMP annual symposium
- Ask Our Experts!
- Legal notice
- Careers
- Confidentiality Policy on Personal Data
- Search
- Paramètres emploi
- Sitemap
- Your spontaneous application
- Our Services
